학술논문
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
Document Type
Article
Author
Laufer, Rachel S.; Driscoll, Amanda J.; Baral, Ranju; Buchwald, Andrea G.; Campbell, James D.; Coulibaly, Flanon; Diallo, Fatoumata; Doumbia, Moussa; Galvani, Alison P.; Haidara, Fadima C.; Kotloff, Karen L.; Keita, Adama M.; Neuzil, Kathleen M.; Orenstein, Evan W.; Orenstein, Lauren A.V.; Pecenka, Clint; Sow, Samba; Tapia, Milagritos D.; Ortiz, Justin R.; Fitzpatrick, Meagan C.
Source
Subject
*RESPIRATORY syncytial virus
*RESPIRATORY infections
*INFANTS
*INVESTMENT policy
*MONOCLONAL antibodies
*MATERNALLY acquired immunity
*LOW-income countries
*
*
*
*
*
*
Language
ISSN
0264-410X
Abstract
• New RSV prevention products can substantially reduce disease burden. • Longer-acting monoclonal antibodies, priced affordably, are likely cost-effective. • Maternal vaccines meeting preferred product characteristics would be cost-effective. • RSV prevention products can provide good value in low-income countries. Low- and middle-income countries have a high burden of respiratory syncytial virus lower respiratory tract infections. A monoclonal antibody administered monthly is licensed to prevent these infections, but it is cost-prohibitive for most low- and middle-income countries. Long-acting monoclonal antibodies and maternal vaccines against respiratory syncytial virus are under development. We estimated the likelihood of respiratory syncytial virus preventive interventions (current monoclonal antibody, long-acting monoclonal antibody, and maternal vaccine) being cost-effective in Mali. We modeled age-specific and season-specific risks of respiratory syncytial virus lower respiratory tract infections within monthly cohorts of infants from birth to six months. We parameterized with respiratory syncytial virus data from Malian cohort studies, as well as product efficacy from clinical trials. Integrating parameter uncertainty, we simulated health and economic outcomes for status quo without prevention, intra-seasonal monthly administration of licensed monoclonal antibody, pre-seasonal birth dose administration of a long-acting monoclonal antibody, and maternal vaccination. We then calculated the incremental cost-effectiveness ratio of each intervention compared to status quo from the perspectives of the government, donor, and society. At a price of $3 per dose and from the societal perspective, current monoclonal antibody, long-acting monoclonal antibody, and maternal vaccine would have incremental cost-effectiveness ratios of $4280 (95% CI $1892 to $122,434), $1656 (95% CI $734 to $9091), and $8020 (95% CI $3501 to $47,047) per disability-adjusted life-year averted, respectively. In Mali, long-acting monoclonal antibody is likely to be cost-effective from both the government and donor perspectives at $3 per dose. Maternal vaccine would need higher efficacy over that measured by a recent trial in order to be considered cost-effective. [ABSTRACT FROM AUTHOR]